TY - DATA T1 - Targeted Tissue Proteomic Analysis of Human Astrocytomas PY - 2012/08/03 AU - Xueping Fang AU - Chenchen Wang AU - Brian M. Balgley AU - Kejia Zhao AU - Weijie Wang AU - Fang He AU - Robert J. Weil AU - Cheng S. Lee UR - https://acs.figshare.com/articles/dataset/Targeted_Tissue_Proteomic_Analysis_of_Human_Astrocytomas/2500081 DO - 10.1021/pr300303t.s021 L4 - https://ndownloader.figshare.com/files/4142956 KW - brain biopsies KW - astrocytoma KW - cell heterogeneity KW - analyte concentration KW - Human AstrocytomasComplicating proteomic analysis KW - protein expression level KW - Targeted Tissue Proteomic Analysis KW - proteomic studies KW - plasma membrane proteins EGFR KW - biomarker selection KW - tissue microdissection KW - tumor cells KW - drive gliomagenesis KW - tumor cell enrichment KW - abundance proteins N2 - Complicating proteomic analysis of whole tissues is the obvious problem of cell heterogeneity in tissues, which often results in misleading or confusing molecular findings. Thus, the coupling of tissue microdissection for tumor cell enrichment with capillary isotachophoresis-based selective analyte concentration not only serves as a synergistic strategy to characterize low abundance proteins, but it can also be employed to conduct comparative proteomic studies of human astrocytomas. A set of fresh frozen brain biopsies were selectively microdissected to provide an enriched, high quality, and reproducible sample of tumor cells. Despite sharing many common proteins, there are significant differences in the protein expression level among different grades of astrocytomas. A large number of proteins, such as plasma membrane proteins EGFR and Erbb2, are up-regulated in glioblastoma. Besides facilitating the prioritization of follow-on biomarker selection and validation, comparative proteomics involving measurements in changes of pathways are expected to reveal the molecular relationships among different pathological grades of gliomas and potential molecular mechanisms that drive gliomagenesis. ER -